{"id":"hgp1201","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Gastrointestinal disorders"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HGP1201 binds to and activates the glucagon-like peptide-1 (GLP-1) receptor on pancreatic beta cells, stimulating glucose-dependent insulin secretion. The drug also slows gastric emptying and promotes satiety, contributing to weight loss and improved metabolic control in patients with type 2 diabetes.","oneSentence":"HGP1201 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:09.434Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT02243319","phase":"PHASE1","title":"Investigating the Pharmacokinetic Drug Interactions Between HGP1201 and HGP0904","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2014-09","conditions":"Healthy","enrollment":24},{"nctId":"NCT02667938","phase":"PHASE3","title":"A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HCP1303 Capsules","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2015-03","conditions":"Benign Prostatic Hyperplasia","enrollment":510},{"nctId":"NCT02715401","phase":"PHASE1","title":"PK and Safety of HCP1303 and Co-administration of HGP1201, HIP1402 Under Fed Condition in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2015-10","conditions":"Erectile Dysfunction, Prostatic Hyperplasia","enrollment":36},{"nctId":"NCT02712411","phase":"PHASE1","title":"Pharmacokinetics and Safety of HCP1303 and Co-administration of HGP1201, HIP1402 in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2015-07","conditions":"Erectile Dysfunction, Prostatic Hyperplasia","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HGP1201","genericName":"HGP1201","companyName":"Hanmi Pharmaceutical Company Limited","companyId":"hanmi-pharmaceutical-company-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HGP1201 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}